INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS
申请人:AstraZeneca AB
公开号:EP0946589B1
公开(公告)日:2003-10-01
TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF
申请人:REGENERON PHARMACEUTICALS, INC.
公开号:EP3908323A2
公开(公告)日:2021-11-17
US6184207B1
申请人:——
公开号:US6184207B1
公开(公告)日:2001-02-06
[EN] TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF<br/>[FR] LIEURS SANS TRACE ET CONJUGUÉS PROTÉIQUES ASSOCIÉS
申请人:REGENERON PHARMA
公开号:WO2020146541A2
公开(公告)日:2020-07-16
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management of the symptoms thereof, associated with inflammatory diseases and autoimmune disorders further associated with the glucocorticoid receptor, glucocorticoid binding, and/or glucocorticoid receptor signalling, including administration of the compounds or payloads via traceless linker-payloads, and protein conjugates thereof.
Solid-Phase Synthesis of Constrained Terminal and Internal Lactam Peptidomimetics
作者:William L. Scott、Jordi Alsina、Joseph H. Kennedy、Martin J. O'Donnell
DOI:10.1021/ol049547z
日期:2004.5.1
Lactams are key components of many peptidomimetic structures. Five- and six-membered lactam peptidomimetics with hydrogen or amino acid side chains at the alpha-position can be constructed from peptide precursors during a solid-phase synthesis. There is no significant racemization of remote stereocenters during synthesis.